Patent intelligence · EP
EP 1603935
SPEZIFISCH AN HGF-REZEPTOR (cMet) BINDENDE PEPTIDE UND DEREN VERWENDUNG
SPEZIFISCH AN HGF-REZEPTOR (cMet) BINDENDE PEPTIDE UND DEREN VERWENDUNG
Patent details — EP 1603935
- Jurisdiction
- EP
- Status
- expired
- Grant date
- Dec 14, 2005
- Expiration
- Dec 9, 2025
- Applicant
- DYAX CORP [US]
- CPC classes
- A61K 38/ 10 A I, A61K 38/ 18 A I, A61K 47/ 48 A I, A61K 49/ 00 A I
Quick answer
EP 1603935 (SPEZIFISCH AN HGF-REZEPTOR (cMet) BINDENDE PEPTIDE UND DEREN VERWENDUNG) is held by DYAX CORP [US]. Status: expired. Granted Dec 14, 2005. Expires Dec 9, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- DYAX CORP [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 38/ 10 A I, A61K 38/ 18 A I, A61K 47/ 48 A I, A61K 49/ 00 A I, A61K 51/ 08 A I, A61K/47543
More from DYAX CORP [US]
Related pharmaceutical patents in our USPTO index.
-
IL 172160
Method for non-invasive quantification of perfusion in a tissue
granted -
EP 2117603
TARGETING UND THERAPEUTISCHE VERBINDUNGEN UND GASGEFÜLLTE MIKROVESIKEL MIT DIESEN VERBINDUNGEN
granted -
WO 2009076388
CONJUGUÉS VECTEUR DE CIBLAGE - PHOSPHOLIPIDE
granted -
CA 2670932
DETECTION DU DETACHEMENT D'UN AGENT DE CONTRASTE IMMOBILISE DANS DES APPLICATIONS D'IMAGERIE MEDICALE
granted -
US 2008107607
TARGETING VECTOR-PHOSPHOLIPID CONJUGATES
granted -
US 2008063603
ULTRASOUND CONTRAST AGENTS AND METHODS OF MAKING AND USING THEM
granted -
CA 2631716
CONJUGUES VECTEUR DE CIBLAGE-PHOSPHOLIPIDES
granted -
US 2007128117
Ultrasound contrast agents and process for the preparation thereof
granted
Frequently asked questions
What is US patent 1603935?
EP 1603935 (SPEZIFISCH AN HGF-REZEPTOR (cMet) BINDENDE PEPTIDE UND DEREN VERWENDUNG) is held by DYAX CORP [US]. Status: expired. Granted Dec 14, 2005. Expires Dec 9, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 1603935?
DYAX CORP [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does EP 1603935 expire?
Our index shows an expiration date of Dec 9, 2025 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.